Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / ADR
-
Shares outstanding
-
50.2M
-
Number of holders
-
107
-
Total 13F shares, excl. options
-
32.7M
-
Shares change
-
+2.43M
-
Total reported value, excl. options
-
$1.61B
-
Value change
-
+$119M
-
Put/Call ratio
-
0.17
-
Number of buys
-
53
-
Number of sells
-
-48
-
Price
-
$49.44
Significant Holders of Immunocore Holdings plc - ADR (IMCR) as of Q1 2023
131 filings reported holding IMCR - Immunocore Holdings plc - ADR as of Q1 2023.
Immunocore Holdings plc - ADR (IMCR) has 107 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32.7M shares
of 50.2M outstanding shares and own 65.07% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (5.65M shares), WELLINGTON MANAGEMENT GROUP LLP (3.38M shares), Rock Springs Capital Management LP (3M shares), BAKER BROS. ADVISORS LP (2.52M shares), FMR LLC (2.09M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.38M shares), Paradigm Biocapital Advisors LP (1.13M shares), GENERAL ATLANTIC, L.P. (950K shares), PICTET ASSET MANAGEMENT SA (889K shares), and MORGAN STANLEY (796K shares).
This table shows the top 107 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.